Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Phase I/II Trial of Anticarcinoembryonic Antigen Radioimmunotherapy, Gemcitabine, and Hepatic Arterial Infusion of Fluorodeoxyuridine Postresection of Liver Metastasis for Colorectal Carcinoma.

Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, Williams LE, Yazaki P, Colcher D, Frankel P, Wu A, Raubitschek A, Shively J, Wong JYC.

Cancer Biother Radiopharm. 2017 Sep;32(7):258-265.

PMID:
28910150
2.

Tumor Uptake of 64Cu-DOTA-Trastuzumab in Patients with Metastatic Breast Cancer.

Mortimer JE, Bading JR, Park JM, Frankel PH, Carroll MI, Tran TT, Poku EK, Rockne RC, Raubitschek AA, Shively JE, Colcher DM.

J Nucl Med. 2018 Jan;59(1):38-43. doi: 10.2967/jnumed.117.193888. Epub 2017 Jun 21. Erratum in: J Nucl Med. 2018 Feb;59(2):346.

3.

Low Dose Focused Ultrasound Induces Enhanced Tumor Accumulation of Natural Killer Cells.

Sta Maria NS, Barnes SR, Weist MR, Colcher D, Raubitschek AA, Jacobs RE.

PLoS One. 2015 Nov 10;10(11):e0142767. doi: 10.1371/journal.pone.0142767. eCollection 2015.

4.

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.

Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2072-5. doi: 10.1016/j.bbmt.2014.07.028. Epub 2014 Jul 29.

5.

Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.

Mortimer JE, Bading JR, Colcher DM, Conti PS, Frankel PH, Carroll MI, Tong S, Poku E, Miles JK, Shively JE, Raubitschek AA.

J Nucl Med. 2014 Jan;55(1):23-9. doi: 10.2967/jnumed.113.122630. Epub 2013 Dec 12.

6.

Exonic transcription factor binding directs codon choice and affects protein evolution.

Stergachis AB, Haugen E, Shafer A, Fu W, Vernot B, Reynolds A, Raubitschek A, Ziegler S, LeProust EM, Akey JM, Stamatoyannopoulos JA.

Science. 2013 Dec 13;342(6164):1367-72. doi: 10.1126/science.1243490.

7.

TLR9 signaling in the tumor microenvironment initiates cancer recurrence after radiotherapy.

Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, Kowolik CM, Chu P, Swiderski P, Diamond DJ, Pal SK, Raubitschek A, Kortylewski M.

Cancer Res. 2013 Dec 15;73(24):7211-21. doi: 10.1158/0008-5472.CAN-13-1314. Epub 2013 Oct 23.

8.

Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.

Nechaev S, Gao C, Moreira D, Swiderski P, Jozwiak A, Kowolik CM, Zhou J, Armstrong B, Raubitschek A, Rossi JJ, Kortylewski M.

J Control Release. 2013 Sep 28;170(3):307-15. doi: 10.1016/j.jconrel.2013.06.007. Epub 2013 Jun 15.

9.

Serial diffusion MRI to monitor and model treatment response of the targeted nanotherapy CRLX101.

Ng TS, Wert D, Sohi H, Procissi D, Colcher D, Raubitschek AA, Jacobs RE.

Clin Cancer Res. 2013 May 1;19(9):2518-27. doi: 10.1158/1078-0432.CCR-12-2738. Epub 2013 Mar 26.

10.

TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.

Zhang Q, Hossain DM, Nechaev S, Kozlowska A, Zhang W, Liu Y, Kowolik CM, Swiderski P, Rossi JJ, Forman S, Pal S, Bhatia R, Raubitschek A, Yu H, Kortylewski M.

Blood. 2013 Feb 21;121(8):1304-15. doi: 10.1182/blood-2012-07-442590. Epub 2013 Jan 3.

11.

A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.

Yazaki PJ, Lee B, Channappa D, Cheung CW, Crow D, Chea J, Poku E, Li L, Andersen JT, Sandlie I, Orcutt KD, Wittrup KD, Shively JE, Raubitschek A, Colcher D.

Protein Eng Des Sel. 2013 Mar;26(3):187-93. doi: 10.1093/protein/gzs096. Epub 2012 Nov 21.

12.

Systematic localization of common disease-associated variation in regulatory DNA.

Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, Reynolds AP, Sandstrom R, Qu H, Brody J, Shafer A, Neri F, Lee K, Kutyavin T, Stehling-Sun S, Johnson AK, Canfield TK, Giste E, Diegel M, Bates D, Hansen RS, Neph S, Sabo PJ, Heimfeld S, Raubitschek A, Ziegler S, Cotsapas C, Sotoodehnia N, Glass I, Sunyaev SR, Kaul R, Stamatoyannopoulos JA.

Science. 2012 Sep 7;337(6099):1190-5. doi: 10.1126/science.1222794. Epub 2012 Sep 5.

13.

Intracerebral CpG immunotherapy with carbon nanotubes abrogates growth of subcutaneous melanomas in mice.

Fan H, Zhang I, Chen X, Zhang L, Wang H, Da Fonseca A, Manuel ER, Diamond DJ, Raubitschek A, Badie B.

Clin Cancer Res. 2012 Oct 15;18(20):5628-38. doi: 10.1158/1078-0432.CCR-12-1911. Epub 2012 Aug 17.

14.

Quantitative, simultaneous PET/MRI for intratumoral imaging with an MRI-compatible PET scanner.

Ng TS, Bading JR, Park R, Sohi H, Procissi D, Colcher D, Conti PS, Cherry SR, Raubitschek AA, Jacobs RE.

J Nucl Med. 2012 Jul;53(7):1102-9. doi: 10.2967/jnumed.111.099861. Epub 2012 Jun 1.

15.

S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.

Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, Shen S, Priceman SJ, Kujawski M, Pal SK, Raubitschek A, Hoon DS, Forman S, Figlin RA, Liu J, Jove R, Yu H.

Cancer Cell. 2012 May 15;21(5):642-54. doi: 10.1016/j.ccr.2012.03.039.

16.

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW.

Blood. 2012 Apr 26;119(17):3940-50. doi: 10.1182/blood-2011-10-387969. Epub 2012 Feb 3.

17.

Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma.

Krishnan A, Palmer JM, Tsai NC, Simpson JR, Nademanee A, Raubitschek A, Thomas SH, Forman SJ.

Biol Blood Marrow Transplant. 2012 Mar;18(3):441-50. doi: 10.1016/j.bbmt.2011.07.016. Epub 2011 Jul 27.

18.

Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improved 64-copper PET imaging.

Li L, Crow D, Turatti F, Bading JR, Anderson AL, Poku E, Yazaki PJ, Carmichael J, Leong D, Wheatcroft D, Raubitschek AA, Hudson PJ, Colcher D, Shively JE.

Bioconjug Chem. 2011 Apr 20;22(4):709-16. doi: 10.1021/bc100464e. Epub 2011 Mar 24. Erratum in: Bioconjug Chem. 2011 Jun 15;22(6):1256. Wheatcroft, Michael P [corrected to Wheatcroft, David].

19.

A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast cancer.

Wong JY, Raubitschek A, Yamauchi D, Williams LE, Wu AM, Yazaki P, Shively JE, Colcher D, Somlo G.

Cancer Biother Radiopharm. 2010 Aug;25(4):387-94. doi: 10.1089/cbr.2010.0783.

20.

Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.

Li L, Turatti F, Crow D, Bading JR, Anderson AL, Poku E, Yazaki PJ, Williams LE, Tamvakis D, Sanders P, Leong D, Raubitschek A, Hudson PJ, Colcher D, Shively JE.

J Nucl Med. 2010 Jul;51(7):1139-46. doi: 10.2967/jnumed.109.074153. Epub 2010 Jun 16.

21.

Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.

James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Budde LE, Till BG, Raubitschek AA, Forman SJ, Press OW.

J Immunol. 2010 Apr 15;184(8):4284-94. doi: 10.4049/jimmunol.0903701. Epub 2010 Mar 10. Erratum in: J Immunol. 2010 Jul 15;185(2):1340.

22.

Minibodies and Multimodal Chromatography Methods: A Convergence of Challenge and Opportunity.

Gagnon P, Cheung CW, Lepin EJ, Wu AM, Sherman MA, Raubitschek AA, Yazaki PJ.

Bioprocess Int. 2010 Feb;8(2):26-35.

23.

ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).

Olafsen T, Sirk SJ, Betting DJ, Kenanova VE, Bauer KB, Ladno W, Raubitschek AA, Timmerman JM, Wu AM.

Protein Eng Des Sel. 2010 Apr;23(4):243-9. doi: 10.1093/protein/gzp081. Epub 2010 Jan 6.

24.

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, Lee H, Scuto A, Liu Y, Yang C, Deng J, Soifer HS, Raubitschek A, Forman S, Rossi JJ, Pardoll DM, Jove R, Yu H.

Nat Biotechnol. 2009 Oct;27(10):925-32. doi: 10.1038/nbt.1564. Epub 2009 Sep 13.

25.

Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.

Olafsen T, Betting D, Kenanova VE, Salazar FB, Clarke P, Said J, Raubitschek AA, Timmerman JM, Wu AM.

J Nucl Med. 2009 Sep;50(9):1500-8. doi: 10.2967/jnumed.108.060426. Epub 2009 Aug 18.

26.

Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.

Numbenjapon T, Wang J, Colcher D, Schluep T, Davis ME, Duringer J, Kretzner L, Yen Y, Forman SJ, Raubitschek A.

Clin Cancer Res. 2009 Jul 1;15(13):4365-73. doi: 10.1158/1078-0432.CCR-08-2619. Epub 2009 Jun 23.

27.

A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.

Shibata S, Raubitschek A, Leong L, Koczywas M, Williams L, Zhan J, Wong JY.

Clin Cancer Res. 2009 Apr 15;15(8):2935-41. doi: 10.1158/1078-0432.CCR-08-2213. Epub 2009 Apr 7.

28.

Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice.

Bading JR, Hörling M, Williams LE, Colcher D, Raubitschek A, Strand SE.

Cancer Biother Radiopharm. 2008 Aug;23(4):399-409. doi: 10.1089/cbr.2007.0457.

29.

Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.

Bartlett DW, Colcher D, Raubitschek AA.

Bioconjug Chem. 2008 Sep;19(9):1927-37. doi: 10.1021/bc800223x. Epub 2008 Aug 23.

30.

Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.

Lazovic J, Jensen MC, Ferkassian E, Aguilar B, Raubitschek A, Jacobs RE.

Clin Cancer Res. 2008 Jun 15;14(12):3832-9. doi: 10.1158/1078-0432.CCR-07-5067.

31.

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW.

Blood. 2008 Sep 15;112(6):2261-71. doi: 10.1182/blood-2007-12-128843. Epub 2008 May 28.

32.

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

James SE, Greenberg PD, Jensen MC, Lin Y, Wang J, Till BG, Raubitschek AA, Forman SJ, Press OW.

J Immunol. 2008 May 15;180(10):7028-38.

33.

Intratumoral immunocytokine treatment results in enhanced antitumor effects.

Johnson EE, Lum HD, Rakhmilevich AL, Schmidt BE, Furlong M, Buhtoiarov IN, Hank JA, Raubitschek A, Colcher D, Reisfeld RA, Gillies SD, Sondel PM.

Cancer Immunol Immunother. 2008 Dec;57(12):1891-902. doi: 10.1007/s00262-008-0519-0. Epub 2008 Apr 26.

34.

Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.

Yazaki PJ, Kassa T, Cheung CW, Crow DM, Sherman MA, Bading JR, Anderson AL, Colcher D, Raubitschek A.

Nucl Med Biol. 2008 Feb;35(2):151-8. doi: 10.1016/j.nucmedbio.2007.10.010.

35.

Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.

Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ.

J Clin Oncol. 2008 Jan 1;26(1):90-5. Epub 2007 Nov 19.

PMID:
18025438
36.

A versatile bifunctional chelate for radiolabeling humanized anti-CEA antibody with In-111 and Cu-64 at either thiol or amino groups: PET imaging of CEA-positive tumors with whole antibodies.

Li L, Bading J, Yazaki PJ, Ahuja AH, Crow D, Colcher D, Williams LE, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2008 Jan;19(1):89-96. Epub 2007 Nov 8.

37.

Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.

Wang J, Jensen M, Lin Y, Sui X, Chen E, Lindgren CG, Till B, Raubitschek A, Forman SJ, Qian X, James S, Greenberg P, Riddell S, Press OW.

Hum Gene Ther. 2007 Aug;18(8):712-25.

PMID:
17685852
38.

Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.

Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE.

J Immunother. 2007 May-Jun;30(4):396-405.

PMID:
17457214
39.

Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy.

Singh H, Serrano LM, Pfeiffer T, Olivares S, McNamara G, Smith DD, Al-Kadhimi Z, Forman SJ, Gillies SD, Jensen MC, Colcher D, Raubitschek A, Cooper LJ.

Cancer Res. 2007 Mar 15;67(6):2872-80.

40.

Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.

Kenanova V, Olafsen T, Williams LE, Ruel NH, Longmate J, Yazaki PJ, Shively JE, Colcher D, Raubitschek AA, Wu AM.

Cancer Res. 2007 Jan 15;67(2):718-26.

41.

Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma.

Mamelak AN, Rosenfeld S, Bucholz R, Raubitschek A, Nabors LB, Fiveash JB, Shen S, Khazaeli MB, Colcher D, Liu A, Osman M, Guthrie B, Schade-Bijur S, Hablitz DM, Alvarez VL, Gonda MA.

J Clin Oncol. 2006 Aug 1;24(22):3644-50.

PMID:
16877732
42.

A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.

Wong JY, Chu DZ, Williams LE, Liu A, Zhan J, Yamauchi DM, Wilczynski S, Wu AM, Yazaki PJ, Shively JE, Leong L, Raubitschek AA.

Cancer Biother Radiopharm. 2006 Apr;21(2):88-100.

PMID:
16706629
43.

Improved biodistribution and radioimmunoimaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody.

Li L, Yazaki PJ, Anderson AL, Crow D, Colcher D, Wu AM, Williams LE, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2006 Jan-Feb;17(1):68-76.

PMID:
16417253
44.

Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.

Crow DM, Williams L, Colcher D, Wong JY, Raubitschek A, Shively JE.

Bioconjug Chem. 2005 Sep-Oct;16(5):1117-25.

PMID:
16173788
45.

T-cell genetic modification for re-directed tumor recognition.

Cooper LJ, Kalos M, DiGiusto D, Brown C, Forman SJ, Raubitschek A, Jensen MC.

Cancer Chemother Biol Response Modif. 2005;22:293-324. Review. No abstract available.

PMID:
16110618
46.

Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody.

Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T, Eschner W, Hansen H, Morschhauser F, Schicha H, Diehl V, Raubitschek A, Engert A.

J Clin Oncol. 2005 Jul 20;23(21):4669-78.

PMID:
16034043
47.

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.

Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A.

Blood. 2005 Oct 15;106(8):2896-902. Epub 2005 Jul 7.

48.

Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.

Olafsen T, Kenanova VE, Sundaresan G, Anderson AL, Crow D, Yazaki PJ, Li L, Press MF, Gambhir SS, Williams LE, Wong JY, Raubitschek AA, Shively JE, Wu AM.

Cancer Res. 2005 Jul 1;65(13):5907-16.

49.

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy.

Nagata S, Ise T, Onda M, Nakamura K, Ho M, Raubitschek A, Pastan IH.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7946-51. Epub 2005 May 19. Erratum in: Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):3007.

50.

Imaging glioma extent with 131I-TM-601.

Hockaday DC, Shen S, Fiveash J, Raubitschek A, Colcher D, Liu A, Alvarez V, Mamelak AN.

J Nucl Med. 2005 Apr;46(4):580-6.

Supplemental Content

Loading ...
Support Center